0.50Open0.50Pre Close0 Volume6 Open Interest10.00Strike Price0.00Turnover1281.75%IV5.09%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.50Extrinsic Value100Contract SizeAmericanOptions Type-0.4716Delta0.3140Gamma20.02Leverage Ratio-7.2669Theta0.0000Rho-9.44Eff Leverage0.0004Vega
Kyverna Therapeutics Stock Discussion
Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome
Kyverna Therapeutics (KYTX) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for KYV-101, its autologous CD19 CAR T-cell therapy, in treating refractory stiff-person syndrome. This designation, based on positive clinical outcomes in Germany, allows Kyverna to receive expert guidance on efficient ...
No comment yet